Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma

A. Pappo, N. R. Schneider, J. M. Sanders, G. R. Buchanan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A 12-year-old girl with nonmetastatic osteogenic sarcoma received treatment with doxorubicin, methotrexate, cisplatin, cyclophosphamide, bleomycin, and dactinomycin. She developed unexplained persistent pancytopenia after completion of chemotherapy. Twenty-three months after the initial diagnosis of osteosarcoma an evaluation revealed a bone marrow pattern consistent with the diagnosis of refractory anemia with excess blasts, and karyotype analysis showed characteristic findings of therapy-related myelodysplasia (loss of chromosomes 5 and 7, as well as 12p and 17p deletions). Bone marrow transplantation from an human leukocyte antigen (HLA)-compatible sibling donor was performed 26 months after the diagnosis of the primary malignancy. Although it is unproven that the alkylating agents administered to this patient were responsible for the myelodysplastic syndrome, careful follow-up of osteosarcoma patients who receive alkylating agents is warranted.

Original languageEnglish (US)
Pages (from-to)1373-1375
Number of pages3
JournalCancer
Volume68
Issue number6
StatePublished - 1991

Fingerprint

Myelodysplastic Syndromes
Osteosarcoma
Alkylating Agents
Refractory Anemia with Excess of Blasts
Chromosomes, Human, Pair 5
Pancytopenia
Chromosomes, Human, Pair 7
Bleomycin
Dactinomycin
HLA Antigens
Bone Marrow Transplantation
Karyotype
Methotrexate
Doxorubicin
Cyclophosphamide
Cisplatin
Siblings
Therapeutics
Bone Marrow
Tissue Donors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pappo, A., Schneider, N. R., Sanders, J. M., & Buchanan, G. R. (1991). Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma. Cancer, 68(6), 1373-1375.

Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma. / Pappo, A.; Schneider, N. R.; Sanders, J. M.; Buchanan, G. R.

In: Cancer, Vol. 68, No. 6, 1991, p. 1373-1375.

Research output: Contribution to journalArticle

Pappo, A, Schneider, NR, Sanders, JM & Buchanan, GR 1991, 'Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma', Cancer, vol. 68, no. 6, pp. 1373-1375.
Pappo, A. ; Schneider, N. R. ; Sanders, J. M. ; Buchanan, G. R. / Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma. In: Cancer. 1991 ; Vol. 68, No. 6. pp. 1373-1375.
@article{df164883eba74a76b102a4902b00846e,
title = "Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma",
abstract = "A 12-year-old girl with nonmetastatic osteogenic sarcoma received treatment with doxorubicin, methotrexate, cisplatin, cyclophosphamide, bleomycin, and dactinomycin. She developed unexplained persistent pancytopenia after completion of chemotherapy. Twenty-three months after the initial diagnosis of osteosarcoma an evaluation revealed a bone marrow pattern consistent with the diagnosis of refractory anemia with excess blasts, and karyotype analysis showed characteristic findings of therapy-related myelodysplasia (loss of chromosomes 5 and 7, as well as 12p and 17p deletions). Bone marrow transplantation from an human leukocyte antigen (HLA)-compatible sibling donor was performed 26 months after the diagnosis of the primary malignancy. Although it is unproven that the alkylating agents administered to this patient were responsible for the myelodysplastic syndrome, careful follow-up of osteosarcoma patients who receive alkylating agents is warranted.",
author = "A. Pappo and Schneider, {N. R.} and Sanders, {J. M.} and Buchanan, {G. R.}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "1373--1375",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma

AU - Pappo, A.

AU - Schneider, N. R.

AU - Sanders, J. M.

AU - Buchanan, G. R.

PY - 1991

Y1 - 1991

N2 - A 12-year-old girl with nonmetastatic osteogenic sarcoma received treatment with doxorubicin, methotrexate, cisplatin, cyclophosphamide, bleomycin, and dactinomycin. She developed unexplained persistent pancytopenia after completion of chemotherapy. Twenty-three months after the initial diagnosis of osteosarcoma an evaluation revealed a bone marrow pattern consistent with the diagnosis of refractory anemia with excess blasts, and karyotype analysis showed characteristic findings of therapy-related myelodysplasia (loss of chromosomes 5 and 7, as well as 12p and 17p deletions). Bone marrow transplantation from an human leukocyte antigen (HLA)-compatible sibling donor was performed 26 months after the diagnosis of the primary malignancy. Although it is unproven that the alkylating agents administered to this patient were responsible for the myelodysplastic syndrome, careful follow-up of osteosarcoma patients who receive alkylating agents is warranted.

AB - A 12-year-old girl with nonmetastatic osteogenic sarcoma received treatment with doxorubicin, methotrexate, cisplatin, cyclophosphamide, bleomycin, and dactinomycin. She developed unexplained persistent pancytopenia after completion of chemotherapy. Twenty-three months after the initial diagnosis of osteosarcoma an evaluation revealed a bone marrow pattern consistent with the diagnosis of refractory anemia with excess blasts, and karyotype analysis showed characteristic findings of therapy-related myelodysplasia (loss of chromosomes 5 and 7, as well as 12p and 17p deletions). Bone marrow transplantation from an human leukocyte antigen (HLA)-compatible sibling donor was performed 26 months after the diagnosis of the primary malignancy. Although it is unproven that the alkylating agents administered to this patient were responsible for the myelodysplastic syndrome, careful follow-up of osteosarcoma patients who receive alkylating agents is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0026006077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026006077&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 1373

EP - 1375

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -